LEADER 02701nam 2200637 a 450 001 9910975336903321 005 20240514042513.0 010 $a1-283-31382-0 010 $a9786613313829 010 $a90-272-7881-4 024 7 $a10.1075/tsl.14 035 $a(CKB)2550000000049977 035 $a(EBL)784332 035 $a(OCoLC)297666732 035 $a(SSID)ssj0000827524 035 $a(PQKBManifestationID)11514376 035 $a(PQKBTitleCode)TC0000827524 035 $a(PQKBWorkID)10829266 035 $a(PQKB)11009288 035 $a(MiAaPQ)EBC784332 035 $a(Au-PeEL)EBL784332 035 $a(CaPaEBR)ebr10509644 035 $a(DE-B1597)719087 035 $a(DE-B1597)9789027278814 035 $a(EXLCZ)992550000000049977 100 $a19871009d1987 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPerspectives on topicalization $ethe case of Japanese Wa /$feditors, John Hinds, Senko K. Maynard, Shoichi Iwasaki 205 $a1st ed. 210 $aAmsterdam ;$aPhiladelphia $cJ. Benjamins Pub. Co.$d1987 215 $a1 online resource (319 pages) $cillustrations 225 1 $aTypological studies in language,$x0167-7373 ;$vv. 14 300 $aDescription based upon print version of record. 311 0 $a0-915027-97-6 311 0 $a90-272-2885-X 320 $aIncludes bibliographical references. 327 $apt. 1. Wa in narrative and expository discourse -- pt. 2. Wa and other syntactic phenomena -- pt. 3. Historical perspectives on Wa -- pt. 4. Pragmatic perspectives on Wa. 330 $aWithin the field of Japanese linguistics, few areas have generated as much controversy as the morpheme wa; traditionally described as a marker of old or contrasted information, its function as a discourse marker has also been studied. This work aims to deepen the understanding of wa through careful examination of the particle at both sentence and discourse levels in old Japanese as well as present-day Japanese. Previous studies have concentrated on syntactic analyses of wa. The contributors to this volume challenge the old approach and uncover new properties of wa. 410 0$aTypological studies in language ;$v14. 606 $aWa (The Japanese word) 615 0$aWa (The Japanese word) 676 $a495.6/2 701 $aHinds$b John$0165936 701 $aMaynard$b Senko K$0863462 701 $aIwasaki$b Sho?ichi$0893789 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910975336903321 996 $aPerspectives on topicalization$94374842 997 $aUNINA LEADER 03441nam 22006135 450 001 9910254273803321 005 20200703132359.0 010 $a981-10-4194-6 024 7 $a10.1007/978-981-10-4194-5 035 $a(CKB)3850000000027470 035 $a(DE-He213)978-981-10-4194-5 035 $a(MiAaPQ)EBC4840975 035 $a(PPN)200511076 035 $a(EXLCZ)993850000000027470 100 $a20170412d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPhase II Clinical Development of New Drugs /$fby Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri 205 $a1st ed. 2017. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2017. 215 $a1 online resource (XVII, 241 p. 25 illus., 17 illus. in color.) 225 1 $aICSA Book Series in Statistics,$x2199-0980 311 $a981-10-4192-X 320 $aIncludes bibliographical references at the end of each chapters. 327 $aChapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials. 330 $aThis book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them. 410 0$aICSA Book Series in Statistics,$x2199-0980 606 $aStatistics 606 $aPharmaceutical technology 606 $aManagement 606 $aStatistics for Life Sciences, Medicine, Health Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/S17030 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aManagement$3https://scigraph.springernature.com/ontologies/product-market-codes/515000 615 0$aStatistics. 615 0$aPharmaceutical technology. 615 0$aManagement. 615 14$aStatistics for Life Sciences, Medicine, Health Sciences. 615 24$aPharmaceutical Sciences/Technology. 615 24$aManagement. 676 $a615.19 700 $aTing$b Naitee$4aut$4http://id.loc.gov/vocabulary/relators/aut$0941785 702 $aChen$b Ding-Geng$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aHo$b Shuyen$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aCappelleri$b Joseph C$4aut$4http://id.loc.gov/vocabulary/relators/aut 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910254273803321 996 $aPhase II Clinical Development of New Drugs$92124861 997 $aUNINA